Abstract 274P
Background
Treatment of head and neck cancer (HNC) is associated with significant acute toxicity, and accurately identifying patients who will not tolerate aggressive treatment remains a challenge. Comorbidity indices are known prognostic factors for HNC survival outcomes. However, no index has been found to be superior, and their performance in predicting early outcomes in HNC patients is not known. This retrospective analysis aims to determine the role of comorbidity indices in predicting 90-day mortality after radical radiotherapy.
Methods
Study population included all non-thyroid, non-metastatic HNC patients who received curative intent radiotherapy, with or without chemotherapy, from 2016-2019 in a single tertiary oncology centre. 260 patients were randomly selected for model building and comparison. Multiple logistic regression was used to analyse the performance of six comorbidity scores – the Charlson Comorbidity Index (CCI), age-adjusted CCI (ACCI), head and neck CCI (HNCCI), Simplified Comorbidity Score (SCS), Adult Comorbidity Evaluation-27 (ACE-27) and the Washington University Head and Neck Comorbidity Index (WUNHCI)– in predicting risk of 90-day mortality after radical treatment. ROC analysis was done to identify the best performing index, on which further analysis was carried out to determine the best cut-off.
Results
46 out of a total of 958 eligible patients (4.8%) died within 90 days after radical treatment in our cohort. Four of the six comorbidity scores were independent predictors of early mortality [CCI: odds ratio (OR) 1.298, p=0.004; ACE-27: OR 2.577, p<0.001; ACCI: OR 1.324, p<0.001; HNCCI: OR 2.056, p=0.001]. From ROC analysis of the remaining four comorbidity indices, ACCI was the best performing model (AUC 0.728). Calculation of the Youden Index yielded a threshold of ACCI score > 3 as the most discriminatory cut-off in predicting 90-day mortality. ACCI >3 was associated with more than 20% mortality in our cohort.
Conclusions
Age-adjusted CCI > 3 is associated with a higher risk of early mortality in HNC patients after radical radiotherapy. This may be taken as an easily accessible reference for discussion in the clinical setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session